Spondyloarthropathies

• US 7,371,725 B2
• Filed: 02/05/2003
• Issued: 05/13/2008
• Est. Priority Date: 02/05/2002
• Status: Expired due to Fees

• Current Assignee: KU Leuven Research & Development
• Original Assignee: KU Leuven Research & Development
• Inventors: Lories, Rik, Luyten, Frank
• Primary Examiner(s): Kemmerer; Elizabeth C.
• Application Number:
  US10/503,751
• Publication Number:
  US 20050106144A1
• Time in Patent Office: 1,924 Days
• Field of Search: None
• US Class Current: 514/12.2
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 38/179 for growth factors; for growth regulators
• CPC Class Codes: A61K 38/18 Growth factors; Growth regulators
• CPC Class Codes: A61K 48/005 characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis

Abstract

The present invention is concerned with a method and composition for use in the medical art. It relates to the prevention and/or minimization of Spondyloarthropathies (SpA) and/or SpA enthesitis. SpA are an important group of chronic inflammatory disorders, affecting both the axial and peripheral skeleton. A particular method and composition optionally including a suitable dispensing device for such compositions can be used for ameliorating or preventing SpA. The invention applies to human and veterinary applications. To date, no single therapeutic approach has proven universally effective in preventing SpA or ameliorating SpA. Therefore, there is a need for compositions and methods which may be used safely and effectively to prevent SpA in a variety of different contexts.

Claims

1. A method for reducing the incidence of or treating Spondyloarthropathic (SpA) enthesitis in a mammal comprising the step of administering to said mammal an amount of noggin effective to reduce the incidence of or to treat SpA enthesitis.

2. The method according to claim 1, wherein said SpA enthesitis is psoriatic arthritis.

3. The method according to claim 1, wherein said noggin is delivered either systemically or locally with an acceptable pharmaceutical carrier.

4. The method according to claim 1, wherein said noggin is co-administered with one or more additional therapeutic agents.